Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The companyâs lead product candidate, AT-001, is a novel aldose reductase inhibitor (ARI) that is being developed for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. Applied Therapeutics is also developing AT-007, a central nervous system penetrant ARI, for the treatment of Galactosemia, a rare pediatric metabolic disease. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of diabetic retinopathy. Source
No articles found.
Novanta is a leading global supplier of core technology solutions that give medica...
Novanta is a leading global supplier of core te...
DarĂŠ Bioscience is a clinical-stage biopharmaceutical company committed to the ad...
DarĂŠ Bioscience is a clinical-stage biopharmac...
At GlycoMimetics, we are committed to helping to make a difference in the lives of...
At GlycoMimetics, we are committed to helping t...
Rocket Pharmaceuticals, Inc. is an emerging, clinical-stage biotechnology company ...
Rocket Pharmaceuticals, Inc. is an emerging, cl...
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the d...
Viking Therapeutics is a clinical-stage biophar...
Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic a...
Lipocine Inc. is a clinical-stage biopharmaceut...
At BioMarin, we focus on developing first-in-class and best-in-class therapeutics ...
At BioMarin, we focus on developing first-in-cl...
Join the National Investor Network and get the latest information with your interests in mind.